| Serial Number | 90370290 |
| Word Mark | TMOD |
| Filing Date | Wednesday, December 9, 2020 |
| Status | 731 - SECOND EXTENSION - GRANTED |
| Status Date | Friday, November 17, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, September 27, 2022 |
| Goods and Services | custom manufacturing of cells, therapeutics and cell therapies for the treatment and prevention of cancer, inflammation and inflammatory diseases; biomanufacturing for others, namely, manufacturing of cells, therapeutics and cell therapeies for the treatment and prevention of cancer, inflammation and inflammatory diseases using biological cells in the manufacturing process; cell therapy manufacturing for others; autologous and allogeneic cell manufacturing for others; manufacturing services for others in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; providing technical information in the field of pharmaceutical manufacturing; custom manufacturing of biological cells, proteins, and antibodies for others for treatment and prevention of cancer, inflammation and inflammatory disease |
| Goods and Services | pharmaceutical products for the treatment and prevention of cancer and inflammatory diseases; therapeutic targets, namely, proteins or protein complexes, for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutic cells, therapeutic proteins and therapeutic antibodies for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; therapeutics and cell therapies in the nature of proteins and protein complexes for the treatment of cancer, inflammation, and inflammatory diseases; engineered cell therapies in the nature of proteins and protein complexes for medical purposes, namely, the treatment and prevention of cancer, inflammation and inflammatory diseases; engineered cell therapy platforms consisting of modified cells, cell receptors, proteins and protein complexes; cell platforms consisting of modified cells, cell receptors, proteins and protein complexes for the treatment and prevention of cancer, inflammation and inflammatory diseases; biological technology platforms consisting of modified cells, cell receptors, proteins and protein complexes for developing and engineering therapeutic cells, therapeutic proteins, therapeutic antibodies, therapeutics and cellular therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; cell platform consisting of modified cells, cell receptors, proteins and protein complexes for autologous and allogeneic cell manufacturing; therapeutics and cell therapies in the nature of proteins and protein complexes targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; gene therapy products, namely, genetically engineered tissues for transplant purposes |
| Goods and Services | Identification and development of, therapeutic targets, namely, proteins and protein complexes, for others for the treatment and prevention of cancer, inflammation and inflammatory diseases; development of therapeutics and cell therapies for the treatment and prevention of cancer, inflammation, and inflammatory diseases; development of therapeutics and cell therapies targeting targets lost in tumors for the treatment and prevention of cancer, inflammation and inflammatory diseases; biotechnology research, development, testing and analysis for the treatment of cancer, inflammation, and inflammatory diseases; scientific research and development services; providing scientific information in the fields of treatment and prevention of cancer, inflammation and inflammatory diseases; research, development, engineering and testing services in the fields of therapeutics, cell therapies, biologics, medicine, and pharmaceuticals; medical laboratory services, namely, tissue material processing and analysis in the field of autologous and allogeneic biologic preparations for medical use; biotechnology laboratory services; scientific and medical laboratory services; genetic engineering services; engineering of biological cells, cellular targets, proteins, and antibodies for others |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 16, 2021 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 16, 2021 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, February 16, 2021 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Party Name | A2 Biotherapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Agoura Hills, CA 91301 |
| Event Date | Event Description |
| Tuesday, November 21, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Friday, November 17, 2023 | SOU EXTENSION 2 GRANTED |
| Friday, November 17, 2023 | SOU EXTENSION 2 FILED |
| Friday, November 17, 2023 | SOU TEAS EXTENSION RECEIVED |
| Thursday, May 11, 2023 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, May 9, 2023 | SOU EXTENSION 1 GRANTED |
| Tuesday, May 9, 2023 | SOU EXTENSION 1 FILED |
| Tuesday, May 9, 2023 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 22, 2022 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, September 27, 2022 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, September 27, 2022 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 7, 2022 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, August 18, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Thursday, August 18, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, August 17, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, August 17, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, July 13, 2022 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Wednesday, July 13, 2022 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Wednesday, July 13, 2022 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Sunday, May 22, 2022 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Sunday, May 22, 2022 | NON-FINAL ACTION E-MAILED |
| Sunday, May 22, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 6, 2022 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Tuesday, March 8, 2022 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Saturday, February 19, 2022 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, February 18, 2022 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, February 17, 2022 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, February 17, 2022 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, August 18, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, August 18, 2021 | NON-FINAL ACTION E-MAILED |
| Wednesday, August 18, 2021 | NON-FINAL ACTION WRITTEN |
| Friday, May 28, 2021 | ASSIGNED TO EXAMINER |
| Tuesday, February 16, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, December 12, 2020 | NEW APPLICATION ENTERED |